Federal Register / Vol. 65, No. 110 / Wednesday, June 7, 2000 / Notices 36151

The NIH announces a new gene

therapy approach which will lower the

risk for atheroscleoric heart disease by

decreasing plasma cholesterol and apoB

levels. Our researchers have shown that

antisense DNA oligonucleotides targeted

for apoB decreased apoB mRNA in a

human liver cell line by up to 80%. This

in turn has led to a new gene therapy

which utilizes a vector designed to

produce antisense mRNA targeted for

apoB. The result is a decrease in liver

apoB production, which is the major

source of circulating apoB. These

oligonucleotides and oligonucleotide

analogs are a novel and useful way of

reducing low density lipoprotein (LDL)

in patients, as well as for research and

diagnostic purposes.

T20/D178 and T21/D107 Are Activators

of Human Phagocyte Formyl Peptide

Receptors

Ji Ming Wang (NCI), Joost J Oppenheim

(NCI), Shao-Bo Su, Wang-Hua Gong,

Philip M. Murphy (NIAID), Ji-Liang

Gao (NIAID)

DHHS Reference No. E–164–99/0 filed

05 May 1999

The use of immunotherapy to treat

inflammatory diseases is prescribed to

thousands each and every year. In use

currently are steroidal and non-steroidal

anti-inflammatory drugs, which have

serious side effects including: adrenal

suppression, gastrointestinal disorders,

increased susceptibility to infections,

fluid retention and bone loss.

The NIH announces a new technology

which can be used in drug discovery

dealing with the modulation of the

immune response. This technology

identifies two polypeptides, T20/DP178

and T21/DP107, which are peptide

domains of the HIV–1 envelope protein

and are potent chemoattractants and

activators of human peripheral blood

phagocytes (monocytes and neutrophils)

but not T lymphocytes. These

polypeptides have been determined to

interact with the Formyl Peptide

Receptors (FPR), which in turn upregulates the immune response by

inducing cell migration and calcium

mobilization. The activation of FPR

class receptors by their agonists also

results in desensitization of cell

responses to other chemotactic factors.

By identifying analogs to T20/DP178

and T21/DP107 and then evaluating

their ability to bind to the FPR, one will

be able to determine if the analog is a

good candidate for either inhibiting or

activating the immune response.

Dated: May 30, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer,

National Institutes of Health.

[FR Doc. 00–14343 Filed 6–6–00; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Clinical Center; Notice of Meeting

Pursuant to section 10(a) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the

Board of Governors of the Warren Grant

Magnuson Clinical Center.

The meeting will be open to the

public, with attendance limited to space

available. Individuals who plan to

attend and need special assistance, such

as sign language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

Name of Committee: Board of Governors of

the Warren Grant Magnuson Clinical Center

Executive Committee.

Date: July 21, 2000.

Time: 8:30 am to 1:30 pm.

Agenda: Topics Related to Clinical Center

Budget.

Place: National Institutes of Health,

Clinical Center Medical Board Room, 2C116,

9000 Rockville Pike, Bethesda, MD 20892.

Contact Person: Maureen E. Gormley,

Executive Secretary, Warren Grant Magnuson

Clinical Center, National Institutes of Health,

Building 10, Room 2C146, Bethesda, MD

20892, 301/496–2897.

Dated: May 31, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–14332 Filed 6–6–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in section 552b(c)(4)

and 552b(c)(6), Title 5 U.S.C., as

amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Special Emphasis Panel, Diet,

Lifestyle and Cancer in U.S. Special

Populations.

Date: June 29, 2000.

Time: 12 pm to 1:30 pm.

Agenda: To review and evaluate grant

applications.

Place: Executive Plaza North, 6130

Executive Boulevard, Conference Room E,

Rockville MD 20852, (Telephone Conference

Call).

Contact Person: Gerald G. Lovinger,

Scientific Review Administrator, Grants

Review Branch, Division of Extramural

Activities, National Cancer Institute, National

Institutes of Health, 6116 Executive

Boulevard, Room 8070, Rockville, MD

20892–7405, 301/496–7987.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of health,

HHS)

Dated: May 31, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–14333 Filed 6–6–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The contract proposals and